IGEG™ Platform Technology

The antibody therapeutics field has been one of the most innovative arenas of biotechnology for decades. Epsilogen believes that the structural characteristics of the IgE molecule offer a rich seam of new opportunities to make better antibodies to treat cancer.

IgE was discovered in 1966 and is larger and more structurally complex than IgG. The IgE molecule has a larger constant region, epsilon, which contains four domains versus the three of IgG. IgE also has seven N-linked glycosylation sites (six of which are utilized) versus IgG’s single site.



Epsilogen is using protein engineering to mix and match individual epsilon chain domains with IgG gamma chain domains to build molecules that have the best characteristics of IgE and IgG.